A RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (GBM)

被引：0

作者：

Ahluwalia, Manmeet ^{[1
]}

Fallah, Jaleh ^{[2
]}

Peereboom, David ^{[3
]}

Schilero, Cathy ^{[3
]}

Ali, Assad ^{[3
]}

Forst, Deborah ^{[4
]}

Wong, Eric ^{[5
]}

Wen, Patrick ^{[6
]}

Reardon, David ^{[6
]}

机构：

[1] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA

[2] Taussig Canc Inst, Cleveland, OH USA

[3] Cleveland Clin, Cleveland, OH 44106 USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[6] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

NEURO-ONCOLOGY | 2019年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

RBTT-08

引用

页码：220 / 220

页数：1

共 50 条

[1] RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA
Ahluwalia, Manmeet
Peereboom, David
Schilero, Cathy
Forst, Deborah
Wong, Eric
Wen, Patrick
Reardon, David
NEURO-ONCOLOGY, 2018, 20 : 234 - 234
[2] RANDOMIZED PHASE II OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM). NIVOLUMAB BENEFITS OLDER POPULATION
Ahluwalia, Manmeet
Peereboom, David
Rauf, Yasmeen
Wen, Patrick
Reardon, David
NEURO-ONCOLOGY, 2021, 23 : 52 - 52
[3] RANDOMIZED PHASE II OPEN-LABEL STUDY OF NIVOLUMAB PLUS STANDARD-DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW-DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM): FINAL REPORT
Ahluwalia, Manmeet
Khosla, Atulya
Rauf, Yasmeen
Peereboom, David
Wen, Patrick Y.
Reardon, David A.
NEURO-ONCOLOGY, 2022, 24 : 64 - 64
[4] A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL)
Ahluwalia, Manmeet Singh
Peereboom, David M.
Ozair, Ahmad
Khosla, Atulya Aman
Rauf, Yasmeen
Nayak, Lakshmi
Ciolfi, Marci
Alban, Tyler
Grabowski, Matthew
Rayman, Pat
Diaz, Marcella
Lathia, Justin
Lee, Eudocia Quant
Wen, Patrick Y.
Reardon, David A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
Ahluwalia, Manmeet Singh
Rauf, Yasmeen
Li, Hong
Wen, Patrick Y.
Peereboom, David M.
Reardon, David A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB (NIVO) PLUS EITHER STANDARD OR REDUCED DOSE BEVACIZUMAB (BEV) IN RECURRENT GLIOBLASTOMA (RGBM)
Ahluwalia, Manmeet
Peereboom, David
Rauf, Yasmeen
Lathia, Justin
Alban, Tyler
Schilero, Cathy
Ciolfi, Marci
LaForest-Roys, Corey
Nayak, Lakshmi
Lee, Eudocia
Wen, Patrick
Reardon, David
NEURO-ONCOLOGY, 2020, 22 : 35 - 35
[7] A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Shiao-Pei Weathers
Xiaosi Han
Diane D. Liu
Charles A. Conrad
Mark R. Gilbert
Monica E. Loghin
Barbara J. O’Brien
Marta Penas-Prado
Vinay K. Puduvalli
Ivo Tremont-Lukats
Rivka R. Colen
W. K. Alfred Yung
John F. de Groot
Journal of Neuro-Oncology, 2016, 129 : 487 - 494
[8] A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Weathers, Shiao-Pei
Han, Xiaosi
Liu, Diane D.
Conrad, Charles A.
Gilbert, Mark R.
Loghin, Monica E.
O'Brien, Barbara J.
Penas-Prado, Marta
Puduvalli, Vinay K.
Tremont-Lukats, Ivo
Colen, Rivka R.
Yung, W. K. Alfred
de Groot, John F.
JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (03) : 487 - 494
[9] A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Weathers, Shiao-Pei S.
Han, Stan Xiaosi
Liu, Diane D.
Conrad, Charles A.
Gilbert, Mark R.
Loghin, Monica Elena
O'Brien, Barbara Jane
Penas-Prado, Marta
Puduvalli, Vinay K.
Tremont-Lukats, Ivo
Yung, W. K. Alfred
De Groot, John Frederick
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[10] VAMANA: A phase 2 study of low-dose bevacizumab plus CCNU in relapsed/recurrent glioblastoma
Menon, Nandini Sharrel
Shah, Minit Jalan
Gupta, Tejpal
Sridhar, Epari
Chatterjee, Abhishek
Dasgupta, Archya
Sahu, Arpita
Sawant, Riddhi
Kapu, Venkatesh
Trikha, Mehak
Shah, Anokhi
Peelay, Zoya Ravish
Puranik, Ameya
Dev, Indraja
Jadhav, Monica
Moiyadi, Aliasgar
Shetty, Prakash
Sahay, Ayushi
Singh, Vikas Kumar
Patil, Vijay Maruti
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA2064 - LBA2064

← 1 2 3 4 5 →